Needham Maintains Buy on Pacira BioSciences, Raises Price Target to $32
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and raises the price target from $30 to $32.
Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and raises the price target from $30 to $32.